Bromfenac

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company: Duract, Wyeth-Ayerst Laboratories
Approval Status: Approved July 1997
Treatment Area: acute pain

General Information

Bromfenac was cleared for marketing by the FDA on July 15, 1997. This provides an alternative to opioids for the management of acute pain. Bromfenac provides fast relief of acute pain without the side effects of opioid analgesics.

Side Effects

Possible adverse side effects include abdominal pain, headache, nausea, and vomiting.

Get Involved

Stroke and You

Stay Informed

Resources

Our Mission Statement

National Stroke Association’s mission is to reduce the incidence and impact of stroke by developing compelling education and programs focused on prevention, treatment, rehabilitation and support for all impacted by stroke.

Visit Our Online Store

National Stroke Association

1-800-STROKES
1-800-787-6537
9707 E. Easter Lane, Suite B
Centennial, CO 80112
info@stroke.org

Clinical Trials Resource Center